ICUI - ICU Medical Inc Stock Price, Fair Value and News

100.61USD-1.16 (-1.14%)Market Closed

Market Summary

USD100.61-1.16

Market Closed

-1.14%

ICUI Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

ICUI Stock Price

View Fullscreen

ICUI RSI Chart

ICUI Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-41.33

Price/Sales (Trailing)

1.09

EV/EBITDA

67.01

Price/Free Cashflow

28.79

ICUI Price/Sales (Trailing)

ICUI Profitability

Operating Margin

34.24%

EBT Margin

-3.47%

Return on Equity

-2.87%

Return on Assets

-1.38%

Free Cashflow Yield

3.47%

ICUI Fundamentals

ICUI Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

-0.35%

Rev. Growth (Qtr)

-3.61%

ICUI Earnings

Earnings (TTM)

-59.3M

Earnings Growth (Yr)

-302.27%

Earnings Growth (Qtr)

-130.19%

Breaking Down ICUI Revenue

Last 7 days

2.4%

Last 30 days

-2.3%

Last 90 days

1.2%

Trailing 12 Months

-51.9%

How does ICUI drawdown profile look like?

ICUI Financial Health

Current Ratio

2.61

Debt/Equity

0.76

Debt/Cashflow

0.11

ICUI Investor Care

Shares Dilution (1Y)

1.25%

Diluted EPS (TTM)

-2.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.3B	0	0	0
2023	2.3B	2.3B	2.2B	2.3B
2022	1.5B	1.8B	2.0B	2.3B
2021	1.3B	1.3B	1.3B	1.3B
2020	1.3B	1.3B	1.3B	1.3B
2019	1.4B	1.3B	1.3B	1.3B
2018	1.4B	1.4B	1.4B	1.4B
2017	537.3M	772.0M	1.0B	1.3B
2016	350.0M	363.0M	374.1M	379.4M
2015	317.5M	322.6M	331.2M	341.7M
2014	312.6M	312.7M	307.3M	309.3M
2013	315.7M	317.0M	318.4M	313.7M
2012	306.2M	305.7M	310.7M	316.9M
2011	290.7M	299.9M	300.9M	302.2M
2010	238.4M	253.6M	275.1M	283.0M
2009	214.4M	219.2M	218.4M	229.0M
2008	192.3M	196.4M	200.6M	204.7M
2007	0	0	0	188.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ICU Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	sanzone virginia ruth	sold (taxes)	-87,291	98.08	-890	vp, general counsel
Mar 15, 2024	jain vivek	sold (taxes)	-261,972	98.08	-2,671	chairman and ceo
Mar 15, 2024	woolson daniel	sold	-77,732	98.2715	-791	vp, gm-infusion capital
Mar 15, 2024	sousa ben	acquired	-	-	1,299	chief information officer
Mar 15, 2024	voigtlander christian b.	sold (taxes)	-174,582	98.08	-1,780	chief operating officer
Mar 15, 2024	sanzone virginia ruth	acquired	-	-	1,624	vp, general counsel
Mar 15, 2024	sousa ben	sold (taxes)	-45,411	98.08	-463	chief information officer
Mar 15, 2024	jain vivek	acquired	-	-	4,871	chairman and ceo
Mar 15, 2024	bonnell brian michael	acquired	-	-	3,247	chief financial officer
Mar 15, 2024	bonnell brian michael	sold (taxes)	-174,582	98.08	-1,780	chief financial officer

Which funds bought or sold ICUI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-36.8	-2,437,000	5,179,000	0.01%
May 07, 2024	Smithfield Trust Co	unchanged	-	2,000	8,000	-%
May 07, 2024	Swiss National Bank	unchanged	-	306,376	4,337,770	-%
May 07, 2024	Inspire Investing, LLC	reduced	-15.31	-34,997	359,742	0.04%
May 07, 2024	Arizona State Retirement System	reduced	-1.67	33,168	605,177	-%
May 07, 2024	Susquehanna Portfolio Strategies, LLC	reduced	-12.96	-259,572	3,829,070	0.09%
May 07, 2024	ASSETMARK, INC	unchanged	-	3,578	50,655	-%
May 07, 2024	SEI INVESTMENTS CO	added	52.11	1,193,440	3,067,850	-%
May 07, 2024	Illinois Municipal Retirement Fund	sold off	-100	-1,234,000	-	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-57.5	-1,294,580	1,090,800	-%

Are Funds Buying or Selling ICUI?

Are funds buying ICUI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICUI

No. of Funds

Unveiling ICU Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 01, 2024	smiths group plc	6.9%	1,670,000	SC 13D/A
Feb 13, 2024	janus henderson group plc	10.8%	2,617,933	SC 13G/A
Feb 13, 2024	fuller & thaler asset management, inc.	6.10%	1,472,050	SC 13G
Feb 08, 2024	wellington management group llp	6.53%	1,575,456	SC 13G/A
Jan 24, 2024	blackrock inc.	10.6%	2,558,515	SC 13G/A
Jan 10, 2024	vanguard group inc	10.11%	2,440,729	SC 13G/A
Dec 11, 2023	t. rowe price investment management, inc.	4.9%	1,173,610	SC 13G/A
Dec 06, 2023	blackrock inc.	10.4%	2,503,520	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	10.1%	2,423,228	SC 13G/A
Feb 10, 2023	janus henderson group plc	10.7%	2,557,226	SC 13G/A

Recent SEC filings of ICU Medical Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 02, 2024	ARS	ARS
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	DEFA14A	DEFA14A
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to ICU Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

ICU Medical Inc News

Latest updates

ICU Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-3.6%	567	588	553	549	569	578	598	561	543	341	336	322	318	320	319	303	329	316	307	312	331
Cost Of Revenue	-	381	-	369	357	377	-	411	393	374	-	208	198	205	-	205	197	207	-	189	208	196
Gross Profit	8.0%	185	172	184	192	192	175	186	168	169	127	128	124	113	120	114	106	121	114	119	104	135
Operating Expenses	6.6%	196	184	161	190	183	175	187	168	211	104	89.00	89.00	86.00	93.00	88.00	87.00	95.00	96.00	86.00	78.00	105
S&GA Expenses	2.0%	158	155	149	151	153	143	153	159	153	81.00	75.00	74.00	72.00	74.00	71.00	67.00	72.00	71.00	66.00	68.00	73.00
R&D Expenses	-2.5%	22.00	22.00	21.00	22.00	20.00	23.00	23.00	23.00	24.00	13.00	12.00	11.00	11.00	12.00	10.00	10.00	11.00	13.00	12.00	11.00	13.00
EBITDA Margin	-20.3%	0.02*	0.03*	0.05*	0.05*	0.03*	0.05*	0.10*	0.11*	0.12*	0.17*	0.17*	0.16*	-	-	-	-	-	-	-	-	-
Interest Expenses	114.3%	24.00	-166	24.00	24.00	23.00	-112	18.00	15.00	13.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	113.8%	3.00	-19.53	-12.60	-12.93	-3.58	-5.91	-8.10	-9.38	-16.73	3.00	7.00	6.00	3.00	4.00	1.00	2.00	4.00	0.00	6.00	5.00	2.00
Earnings Before Taxes	-Infinity%	-36.77	-	-5.37	-22.86	-13.39	-	-21.31	-16.85	-54.80	-	38.00	35.00	27.00	30.00	26.00	21.00	20.00	21.00	33.00	28.00	33.00
EBT Margin	-24.7%	-0.03*	-0.03*	-0.03*	-0.03*	-0.05*	-0.02*	-0.03*	0.00*	0.03*	0.10*	0.10*	0.09*	-	-	-	-	-	-	-	-	-
Net Income	-130.2%	-39.47	-17.15	7.00	-9.93	-9.81	-15.54	-13.21	-7.47	-38.07	20.00	31.00	28.00	24.00	26.00	25.00	19.00	17.00	21.00	27.00	23.00	31.00
Net Income Margin	-100.2%	-0.03*	-0.01*	-0.01*	-0.02*	-0.02*	-0.03*	-0.02*	0.00*	0.03*	0.08*	0.08*	0.08*	-	-	-	-	-	-	-	-	-
Free Cashflow	-51.3%	30.00	61.00	14.00	-19.76	27.00	-23.31	-18.37	-85.82	-24.95	61.00	62.00	39.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.1%	4,288	4,378	4,377	4,463	4,471	4,516	4,450	4,590	4,747	1,881	1,839	1,803	1,765	1,764	1,730	1,859	1,817	1,692	1,638	1,623	1,613
Current Assets	-2.7%	1,188	1,221	1,219	1,245	1,213	1,235	1,199	1,190	1,174	1,030	1,011	973	928	921	900	1,037	1,002	882	944	930	921
Cash Equivalents	-1.1%	251	254	197	196	221	209	244	256	329	553	519	462	424	396	351	446	420	269	316	292	296
Inventory	-2.3%	693	709	760	775	748	696	625	583	536	290	292	300	300	315	322	323	312	338	344	330	322
Net PPE	-1.7%	603	613	609	617	624	636	656	668	674	468	458	459	459	467	456	455	456	456	444	437	433
Goodwill	-0.9%	1,459	1,472	1,444	1,464	1,463	1,449	1,370	1,421	1,527	43.00	33.00	33.00	33.00	33.00	33.00	32.00	31.00	31.00	11.00	11.00	11.00
Current Liabilities	-5.5%	455	482	464	484	462	495	489	486	494	201	185	184	180	195	185	359	357	248	255	260	238
Long Term Debt	-0.7%	1,566	1,578	1,589	1,601	1,612	1,624	1,630	1,636	1,642	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	0%	51.00	51.00	46.00	40.00	35.00	30.00	24.00	19.00	14.00	-	-	-	-	-	-	150	150	-	-	-	-
LT Debt, Non Current	-	-	-	1,589	1,601	1,612	1,624	1,630	1,636	1,642	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-2.6%	2,068	2,123	2,098	2,115	2,100	2,090	2,013	2,086	2,179	1,616	1,590	1,557	1,521	1,502	1,452	1,412	1,376	1,377	1,340	1,318	1,283
Retained Earnings	-4.9%	768	808	825	818	828	838	853	866	874	912	892	861	832	809	783	758	739	722	701	675	652
Additional Paid-In Capital	0.3%	1,371	1,366	1,356	1,345	1,340	1,331	1,323	1,310	1,306	721	711	706	702	693	683	675	666	669	660	658	660
Shares Outstanding	0.9%	24.00	24.00	24.00	24.00	24.00	24.00	24.00	24.00	24.00	21.00	21.00	21.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,601	-	-	-	-	-	-	-	-	-	-	-	3,306	-	-	-	4,836	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-49.8%	45,791	91,269	35,161	-1,474	41,245	-1,711	2,309	-61,385	-1,342	82,621	78,835	54,762	51,320	78,526	75,486	29,221	39,519	48,864	50,796	23,268	-21,010
Share Based Compensation	8.5%	11,598	10,685	10,947	9,773	9,158	7,428	8,743	7,762	12,092	8,105	6,533	6,681	6,022	5,340	6,265	5,410	6,939	5,757	3,723	6,229	6,209
Cashflow From Investing	41.7%	-17,862	-30,650	-24,508	-17,606	-15,183	-23,998	-12,528	-5,192	-1,867,750	-32,941	-21,086	-17,779	-18,881	-40,903	-24,080	-9,684	-23,472	-100,999	-23,900	-31,476	-10,513
Cashflow From Financing	-242.0%	-26,845	-7,849	-6,396	-5,897	-15,837	-10,385	2,530	-4,030	1,648,917	-15,279	1,108	301	-3,000	4,426	-148,588	5,736	138,386	3,331	93.00	2,901	-17,232

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ICUI Income Statement

2024-03-31

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES:
TOTAL REVENUES	$ 566,655	$ 568,649
Cost of goods sold	381,411	376,608
Gross Profit	185,244	192,041
OPERATING EXPENSES:
Selling, general and administrative	157,657	152,572
Research and development	21,842	19,761
Restructuring, strategic transaction and integration	16,105	11,013
Change in fair value of contingent earn-out	295	(700)
TOTAL OPERATING EXPENSES	195,899	182,646
(LOSS) INCOME FROM OPERATIONS	(10,655)	9,395
Interest Expense,net	(23,772)	(22,515)
OTHER EXPENSE, net	(2,341)	(269)
Loss before income taxes	(36,768)	(13,389)
BENEFIT FOR INCOME TAXES	(2,703)	3,577
NET LOSS	$ (39,471)	$ (9,812)
NET LOSS PER SHARE
Basic (in dollars per share)	$ (1.63)	$ (0.41)
Diluted (in dollars per share)	$ (1.63)	$ (0.41)
WEIGHTED AVERAGE NUMBER OF SHARES
Basic (in shares)	24,222	24,014
Diluted (in shares)	24,222	24,014

ICUI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

CURRENT ASSETS:

Cash and Cash Equivalents

$ 251,423

$ 254,222

^[1]

Short-term investment securities

501

^[1]

TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES

251,423

254,723

^[1]

Accounts receivable, net of allowance for doubtful accounts

145,186

161,566

^[1]

Inventories

693,006

709,360

^[1]

Prepaid income taxes

15,476

21,983

^[1]

Prepaid expenses and other current assets

82,636

73,640

^[1]

TOTAL CURRENT ASSETS

1,187,727

1,221,272

^[1]

PROPERTY, PLANT AND EQUIPMENT, net

602,617

612,909

^[1]

Operating Lease Right-of-Use Asset

64,928

69,909

^[1]

GOODWILL

1,459,368

1,472,446

^[1]

INTANGIBLE ASSETS, net

836,904

870,588

^[1]

Deferred Income Taxes

40,203

37,295

OTHER ASSETS

96,651

94,020

^[1]

TOTAL ASSETS

4,288,398

4,378,439

^[1]

CURRENT LIABILITIES:

Accounts payable

152,480

150,030

^[1]

Accrued liabilities

247,896

268,215

^[1]

Current portion of long-term debt

51,000

Income tax payable

2,484

7,714

^[1]

Contingent earn-out liability

1,500

4,879

TOTAL CURRENT LIABILITIES

455,360

481,838

^[1]

Contingent Earn-Out Liability

4,286

3,991

^[1]

Long-term Debt

1,566,298

1,577,770

Other long-term liabilities

102,594

100,497

DEFERRED INCOME TAXES

55,585

55,873

^[1]

INCOME TAX LIABILITY

36,445

35,060

^[1]

COMMITMENTS AND CONTINGENCIES

^[1]

STOCKHOLDERS' EQUITY:

Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none

^[1]

Common stock, $0.10 par value - Authorized-80,000 shares

2,441

2,414

^[1]

Additional paid-in capital

1,371,244

1,366,493

^[1]

Treasury Stock, at cost

(4,692)

(262)

^[1]

Retained earnings

768,375

807,846

^[1]

Accumulated other comprehensive loss

(69,538)

(53,081)

^[1]

TOTAL STOCKHOLDERS' EQUITY

2,067,830

2,123,410

^[1]

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$ 4,288,398

$ 4,378,439

^[1]

[1]	December 31, 2023 balances were derived from audited consolidated financial statements.

About ICU Medical Inc

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 brand; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; professional services; critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

CEO	Mr. Vivek Jain
WEBSITE	icumed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	14500

ICU Medical Inc Frequently Asked Questions

What is the ticker symbol for ICU Medical Inc? What does ICUI stand for in stocks?

ICUI is the stock ticker symbol of ICU Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ICU Medical Inc (ICUI)?

As of Wed May 08 2024, market cap of ICU Medical Inc is 2.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICUI stock?

You can check ICUI's fair value in chart for subscribers.

What is the fair value of ICUI stock?

You can check ICUI's fair value in chart for subscribers. The fair value of ICU Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ICU Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICUI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ICU Medical Inc a good stock to buy?

The fair value guage provides a quick view whether ICUI is over valued or under valued. Whether ICU Medical Inc is cheap or expensive depends on the assumptions which impact ICU Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICUI.

What is ICU Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, ICUI's PE ratio (Price to Earnings) is -41.33 and Price to Sales (PS) ratio is 1.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICUI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ICU Medical Inc's stock?

In the past 10 years, ICU Medical Inc has provided 0.054 (multiply by 100 for percentage) rate of return.